{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:44:28Z","timestamp":1785897868932,"version":"3.56.0"},"reference-count":143,"publisher":"Elsevier","isbn-type":[{"value":"9780443432361","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI080607"],"award-info":[{"award-number":["R01 AI080607"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AGMT00009888"],"award-info":[{"award-number":["AGMT00009888"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA248111"],"award-info":[{"award-number":["R01 CA248111"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 AI190589"],"award-info":[{"award-number":["R21 AI190589"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008169","name":"Minneapolis Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007482","name":"Arizona State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.acr.2026.02.002","type":"book-chapter","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:19:40Z","timestamp":1773058780000},"page":"91-127","source":"Crossref","is-referenced-by-count":0,"title":["Cancer immunotherapy with oncolytic myxoma virus"],"prefix":"10.1016","author":[{"given":"Jacqueline","family":"Carmona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4252-4462","authenticated-orcid":false,"given":"Deon","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masmudur M.","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/bs.acr.2026.02.002_bib0001","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide reductase and cancer: Biological mechanisms and targeted therapies","volume":"34","author":"Aye","year":"2015","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0002","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0003","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/13550280701591526","article-title":"Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells","volume":"13","author":"Barrett","year":"2007","journal-title":"J Neurovirol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/smim.2000.0298","article-title":"Immunomodulatory proteins of myxoma virus","volume":"13","author":"Barrett","year":"2001","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1128\/JVI.01633-06","article-title":"M135R is a novel cell surface virulence factor of myxoma virus","volume":"81","author":"Barrett","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/bs.acr.2026.02.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.32","article-title":"Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice","volume":"3","author":"Bartee","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.002_bib0007","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.bbmt.2012.04.004","article-title":"Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus","volume":"18","author":"Bartee","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0008","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cyto.2009.06.006","article-title":"Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta","volume":"47","author":"Bartee","year":"2009","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.002_bib0009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clml.2015.12.005","article-title":"Myxoma virus induces ligand independent extrinsic apoptosis in human myeloma cells","volume":"16","author":"Bartee","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.002_bib0010","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-16-1638","article-title":"Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy","volume":"77","author":"Bartee","year":"2017","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0011","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2014.01.002","article-title":"Viruses for tumor therapy","volume":"15","author":"Bell","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/bs.acr.2026.02.002_bib0012","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev.micro.62.081307.163009","article-title":"Viral subversion of apoptotic enzymes: Escape from death row","volume":"62","author":"Best","year":"2008","journal-title":"Annu Rev Microbiol"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0013","doi-asserted-by":"crossref","first-page":"e2836","DOI":"10.1038\/cddis.2017.67","article-title":"Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","volume":"8","author":"Bhat","year":"2017","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.002_bib0014","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cytogfr.2006.05.001","article-title":"IL-15\/IL-15 receptor biology: A guided tour through an expanding universe","volume":"17","author":"Budagian","year":"2006","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.002_bib0015","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1006\/viro.1999.0001","article-title":"The complete DNA sequence of myxoma virus","volume":"264","author":"Cameron","year":"1999","journal-title":"Virology"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.002_bib0016","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/v17081058","article-title":"A replication-defective myxoma virus inducing pro-inflammatory responses as monotherapy and an adjuvant to chemo- and DC immuno-therapy for ovarian cancer","volume":"17","author":"Cannon","year":"2025","journal-title":"Viruses"},{"issue":"39","key":"10.1016\/bs.acr.2026.02.002_bib0017","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1016\/j.vaccine.2013.05.056","article-title":"Oncolytic myxoma virus: The path to clinic","volume":"31","author":"Chan","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0018","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nrmicro.2016.45","article-title":"Viral evasion of intracellular DNA and RNA sensing","volume":"14","author":"Chan","year":"2016","journal-title":"Nature Reviews Microbiology"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.002_bib0019","first-page":"830","article-title":"Progress in oncolytic viruses modified with nanomaterials for intravenous application","volume":"20","author":"Chen","year":"2023","journal-title":"Cancer Biol Med"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.clnves.2025.100034","article-title":"Ribonucleotide reductases in cancer: Mechanisms, clinical progress, and prospects","volume":"1","author":"Chen","year":"2025","journal-title":"Cell Investigation"},{"key":"10.1016\/bs.acr.2026.02.002_bib0021","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.omto.2021.07.014","article-title":"Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma","volume":"22","author":"Christie","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.002_bib0022","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/cancers14020337","article-title":"Systemic delivery of mLIGHT-armed myxoma virus is therapeutic for later-stage syngeneic murine lung metastatic osteosarcoma","volume":"14","author":"Christie","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: An EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010316","article-title":"Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes\/macrophages","volume":"18","author":"Conrad","year":"2022","journal-title":"PLoS Pathog"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.002_bib0025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/hum.2009.028","article-title":"Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus","volume":"20","author":"Doronin","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1016\/bs.acr.2026.02.002_bib0026","first-page":"1","article-title":"Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma","volume":"2","author":"Doty","year":"2013","journal-title":"Oncolytic Virother"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.002_bib0027","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1110\/ps.062720107","article-title":"Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2","volume":"16","author":"Douglas","year":"2007","journal-title":"Protein Sci"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006388","article-title":"Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus","volume":"11","author":"Dryja","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/bs.acr.2026.02.002_bib0029","first-page":"1","article-title":"Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma","volume":"4","author":"Dunlap","year":"2015","journal-title":"Oncolytic Virother"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.002_bib0030","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3390\/v17081145","article-title":"The role of myxoma virus immune modulators and host range factors in pathogenesis and species leaping","volume":"17","author":"Enow","year":"2025","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.002_bib0031","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1158\/0008-5472.CAN-08-0045","article-title":"Interleukin-15\/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells","volume":"68","author":"Epardaud","year":"2008","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.002_bib0032","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0033","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1590\/S0074-02761956000100011","article-title":"Evolutionary aspects of Myxomatosis in Australia","volume":"54","author":"Fenner","year":"1956","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.002_bib0034","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1017\/S0022172400044521","article-title":"Epidemiological consequences of the mechanical transmission of myxomatosis by mosquitoes","volume":"54","author":"Fenner","year":"1956","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/bs.acr.2026.02.002_bib0035","series-title":"Myxomatosis","author":"Fenner","year":"1965"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.002_bib0036","first-page":"400","article-title":"The pathogenesis of infectious myxomatosis; the mechanism of infection and the immunological response in the European rabbit (Oryctolagus cuniculus)","volume":"34","author":"Fenner","year":"1953","journal-title":"Br J Exp Pathol"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.002_bib0037","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ni.2231","article-title":"Sensing and reacting to microbes through the inflammasomes","volume":"13","author":"Franchi","year":"2012","journal-title":"Nat Immunol"},{"issue":"21","key":"10.1016\/bs.acr.2026.02.002_bib0038","doi-asserted-by":"crossref","first-page":"8480","DOI":"10.1074\/jbc.RA118.006040","article-title":"Myxoma virus M013 protein antagonizes NF-\u03baB and inflammasome pathways via distinct structural motifs","volume":"294","author":"Garg","year":"2019","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/bs.acr.2026.02.002_bib0039","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1128\/JVI.00935-06","article-title":"Poxviral regulation of the host NF-kappaB response: The vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells","volume":"80","author":"Gedey","year":"2006","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000444","article-title":"The combination of TIM3-based checkpoint blockade and oncolytic virotherapy regresses established solid tumors","volume":"46","author":"Gowan","year":"2023","journal-title":"J Immunother"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0041","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ccr.2011.08.012","article-title":"Tumor entrained neutrophils inhibit seeding in the premetastatic lung","volume":"20","author":"Granot","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0042","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1128\/JVI.76.6.2912-2923.2002","article-title":"Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins","volume":"76","author":"Guerin","year":"2002","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0043","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.002_bib0044","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/bs.acr.2026.02.002_bib0046","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fonc.2017.00195","article-title":"Oncolytic viruses-interaction of virus and tumor cells in the battle to eliminate cancer","volume":"7","author":"Howells","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/bs.acr.2026.02.002_bib0047","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jconrel.2023.01.034","article-title":"Liposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma","volume":"354","author":"Jahani","year":"2023","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.002_bib0048","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0049","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3390\/cancers13061394","article-title":"Myxoma virus expressing LIGHT (TNFSF14) pre-loaded into adipose-derived mesenchymal stem cells is effective treatment for murine pancreatic adenocarcinoma","volume":"13","author":"Jazowiecka-Rakus","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/bs.acr.2026.02.002_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011225","article-title":"Adipose-derived stem cells as carrier of pro-apoptotic oncolytic myxoma virus: To cross the blood-brain barrier and treat murine glioma","volume":"25","author":"Jazowiecka-Rakus","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.002_bib0051","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3390\/cancers14082022","article-title":"Combination of LIGHT (TNFSF14)-armed myxoma virus pre-loaded into ADSCs and gemcitabine in the treatment of experimental orthotopic murine pancreatic adenocarcinoma","volume":"14","author":"Jazowiecka-Rakus","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.acr.2026.02.002_bib0052","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.omto.2020.07.003","article-title":"Myxoma virus-loaded mesenchymal stem cells in experimental oncolytic therapy of murine pulmonary melanoma","volume":"18","author":"Jazowiecka-Rakus","year":"2020","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0053","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0054","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2005.10.003","article-title":"A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection","volume":"23","author":"Johnston","year":"2005","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0055","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1172\/JCI121323","article-title":"Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival","volume":"129","author":"Kellish","year":"2019","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.002_bib0056","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: Genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0057","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/v7031020","article-title":"Myxoma virus and the Leporipoxviruses: An evolutionary paradigm","volume":"7","author":"Kerr","year":"2015","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.002_bib0058","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1038\/leu.2009.219","article-title":"Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells","volume":"23","author":"Kim","year":"2009","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/bs.acr.2026.02.002_bib0059","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1038\/onc.2010.137","article-title":"The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status","volume":"29","author":"Kim","year":"2010","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.002_bib0060","doi-asserted-by":"crossref","first-page":"e00207","DOI":"10.1128\/JVI.00207-19","article-title":"By binding CD80 and CD86, the vaccinia virus M2 protein blocks their interactions with both CD28 and CTLA4 and potentiates CD80 binding to PD-L1","volume":"93","author":"Kleinpeter","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/bs.acr.2026.02.002_bib0061","first-page":"105","article-title":"Subversion of programed cell death by poxviruses","volume":"442","author":"Koehler","year":"2023","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0062","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.molcel.2007.02.004","article-title":"A structural viral mimic of prosurvival Bcl-2: A pivotal role for sequestering proapoptotic Bax and Bak","volume":"25","author":"Kvansakul","year":"2007","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0063","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: A review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.002_bib0064","doi-asserted-by":"crossref","first-page":"e1558","DOI":"10.1002\/wrna.1558","article-title":"Protein kinase R and its cellular regulators in cancer: An active player or a surveillant?","volume":"11","author":"Lee","year":"2020","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-025-01664-8","article-title":"IL-15: From discovery to FDA approval","volume":"18","author":"Li","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/bs.acr.2026.02.002_bib0066","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2016.12.002","article-title":"Ex vivo oncolytic virotherapy with myxoma virus arms multiple allogeneic bone marrow transplant leukocytes to enhance graft versus tumor","volume":"4","author":"Lilly","year":"2017","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0067","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0068","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1128\/JVI.02262-14","article-title":"SAMD9 is an innate antiviral host factor with stress response properties that can be antagonized by poxviruses","volume":"89","author":"Liu","year":"2015","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0069","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.coviro.2012.09.012","article-title":"The poxvirus C7L host range factor superfamily","volume":"2","author":"Liu","year":"2012","journal-title":"Curr Opin Virol"},{"issue":"14\u201315","key":"10.1016\/bs.acr.2026.02.002_bib0070","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.micinf.2010.08.012","article-title":"The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics","volume":"12","author":"Liu","year":"2010","journal-title":"Microbes Infect"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.002_bib0071","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1128\/JVI.02243-10","article-title":"M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells","volume":"85","author":"Liu","year":"2011","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0072","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/cdd.2014.143","article-title":"Autosis and autophagic cell death: The dark side of autophagy","volume":"22","author":"Liu","year":"2015","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.002_bib0073","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0889-8588(05)70378-6","article-title":"Toxicity of chemotherapy","volume":"10","author":"Lowenthal","year":"1996","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.002_bib0074","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/0008-5472.CAN-09-1510","article-title":"Myxoma virus virotherapy for glioma in immunocompetent animal models: Optimizing administration routes and synergy with rapamycin","volume":"70","author":"Lun","year":"2010","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/bs.acr.2026.02.002_bib0075","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1158\/0008-5472.CAN-05-1201","article-title":"Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas","volume":"65","author":"Lun","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0076","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11912-022-01341-w","article-title":"Oncolytic viruses and cancer immunotherapy","volume":"25","author":"Malhotra","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.002_bib0077","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1128\/JVI.77.2.1427-1440.2003","article-title":"The PHD\/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4","volume":"77","author":"Mansouri","year":"2003","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0078","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: Challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0079","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrmicro1099","article-title":"Poxvirus tropism","volume":"3","author":"McFadden","year":"2005","journal-title":"Nature Reviews Microbiology"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.002_bib0080","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0092-8674(90)90374-N","article-title":"Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon","volume":"62","author":"Meurs","year":"1990","journal-title":"Cell"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.002_bib0081","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a010199","article-title":"Poxvirus DNA replication","volume":"5","author":"Moss","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.002_bib0082","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0898-6568(01)00271-6","article-title":"The protein kinase B\/Akt signalling pathway in human malignancy","volume":"14","author":"Nicholson","year":"2002","journal-title":"Cell Signal"},{"key":"10.1016\/bs.acr.2026.02.002_bib0083","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.virol.2017.01.004","article-title":"An interaction domain in human SAMD9 is essential for myxoma virus host-range determinant M062 antagonism of host anti-viral function","volume":"503","author":"Nounamo","year":"2017","journal-title":"Virology"},{"key":"10.1016\/bs.acr.2026.02.002_bib0084","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omto.2017.08.002","article-title":"Myxoma virus optimizes cisplatin for the treatment of ovarian cancer in vitro and in a syngeneic murine dissemination model","volume":"6","author":"Nounamo","year":"2017","journal-title":"Mol Ther Oncolytics"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.002_bib0085","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.tcb.2017.05.007","article-title":"Apoptosis and necroptosis as host defense strategies to prevent viral infection","volume":"27","author":"Orzalli","year":"2017","journal-title":"Trends Cell Biol"},{"key":"10.1016\/bs.acr.2026.02.002_bib0086","article-title":"Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy","volume":"13","author":"Palanivelu","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.002_bib0087","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.20892\/j.issn.2095-3941.2024.0390","article-title":"Improving systemic delivery of oncolytic virus by cellular carriers","volume":"21","author":"Peng","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0088","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/pharmaceutics17060769","article-title":"Adenoviruses encapsulated in PEGylated DOTAP-folate liposomes are protected from the pre-existing humoral immune response","volume":"17","author":"Phung","year":"2025","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.002_bib0089","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/neuonc\/now006","article-title":"M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma","volume":"18","author":"Pisklakova","year":"2016","journal-title":"Neuro Oncol"},{"issue":"7578","key":"10.1016\/bs.acr.2026.02.002_bib0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature15529","article-title":"Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis","volume":"527","author":"Rabinovich","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0091","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15941-1","article-title":"Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells","volume":"7","author":"Rahman","year":"2017","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/bs.acr.2026.02.002_bib0092","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00151-21","article-title":"RNA helicase A\/DHX9 forms unique cytoplasmic antiviral granules that restrict oncolytic myxoma virus replication in human cancer cells","volume":"95","author":"Rahman","year":"2021","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.002_bib0093","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003465","article-title":"Myxoma virus protein M029 is a dual function immunomodulator that inhibits PKR and also conscripts RHA\/DHX9 to promote expanded host tropism and viral replication","volume":"9","author":"Rahman","year":"2013","journal-title":"PLoS Pathog"},{"issue":"23","key":"10.1016\/bs.acr.2026.02.002_bib0094","doi-asserted-by":"crossref","first-page":"12505","DOI":"10.1128\/JVI.00410-11","article-title":"Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-\u03baB innate response pathways","volume":"85","author":"Rahman","year":"2011","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/jcm9010171","article-title":"Oncolytic virotherapy with myxoma virus","volume":"9","author":"Rahman","year":"2020","journal-title":"J Clin Med"},{"issue":"21","key":"10.1016\/bs.acr.2026.02.002_bib0096","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic viruses: Newest frontier for cancer immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.002_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000635","article-title":"Co-regulation of NF-kappaB and inflammasome-mediated inflammatory responses by myxoma virus pyrin domain-containing protein M013","volume":"5","author":"Rahman","year":"2009","journal-title":"PLoS Pathog"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.002_bib0098","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/2767-9764.CRC-22-0483","article-title":"Nuclear export inhibitor selinexor enhances oncolytic myxoma virus therapy against cancer","volume":"3","author":"Rahman","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/bs.acr.2026.02.002_bib0099","article-title":"Antagonizing the SAMD9 pathway is key to myxoma virus host shut-off and immune evasion","author":"Raza","year":"2024","journal-title":"bioRxiv"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.002_bib0100","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12032-025-02830-1","article-title":"Unlocking glioblastoma: Breakthroughs in molecular mechanisms and next-generation therapies","volume":"42","author":"Rizwani","year":"2025","journal-title":"Med Oncol"},{"issue":"793","key":"10.1016\/bs.acr.2026.02.002_bib0101","doi-asserted-by":"crossref","first-page":"eadk3702","DOI":"10.1126\/scitranslmed.adk3702","article-title":"The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming","volume":"17","author":"Rolig","year":"2025","journal-title":"Sci Transl Med"},{"issue":"1\u20132","key":"10.1016\/bs.acr.2026.02.002_bib0102","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijpharm.2017.04.006","article-title":"Cationic liposome-mediated delivery of reovirus enhances the tumor cell-killing efficiencies of reovirus in reovirus-resistant tumor cells","volume":"524","author":"Sakurai","year":"2017","journal-title":"Int J Pharm"},{"issue":"24","key":"10.1016\/bs.acr.2026.02.002_bib0103","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1158\/0008-5472.CAN-24-1846","article-title":"AKT and the hallmarks of cancer","volume":"84","author":"Sementino","year":"2024","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.002_bib0104","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00210-023-02781-2","article-title":"Effects of chemotherapy on the immune system: Implications for cancer treatment and patient outcomes","volume":"397","author":"Sharma","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.002_bib0105","first-page":"571","article-title":"Oncolytic viruses & their specific targeting to tumour cells","volume":"136","author":"Singh","year":"2012","journal-title":"Indian J Med Res"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10059-010-0014-2","article-title":"Autophagy in viral replication and pathogenesis","volume":"29","author":"Sir","year":"2010","journal-title":"Mol Cells"},{"key":"10.1016\/bs.acr.2026.02.002_bib0107","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3389\/fimmu.2020.00922","article-title":"TNFSF14: LIGHTing the way for effective cancer immunotherapy","volume":"11","author":"Skeate","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0108","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1297-9716-42-76","article-title":"The current status and future directions of myxoma virus, a master in immune evasion","volume":"42","author":"Spiesschaert","year":"2011","journal-title":"Vet Res"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.002_bib0109","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.177.9.6072","article-title":"Combined IL-15\/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo","volume":"177","author":"Stoklasek","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.002_bib0110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0111","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1128\/JVI.80.3.1140-1151.2006","article-title":"Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of bax at the mitochondria","volume":"80","author":"Su","year":"2006","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0112","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1128\/JVI.80.3.1140-1151.2006","article-title":"Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria","volume":"80","author":"Su","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/bs.acr.2026.02.002_bib0113","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: Pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/bs.acr.2026.02.002_bib0114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/OV.S189832","article-title":"A cautionary note on the selectivity of oncolytic poxviruses","volume":"8","author":"Tang","year":"2019","journal-title":"Oncolytic Virother"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.002_bib0115","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1158\/1078-0432.CCR-18-3626","article-title":"Synergistic combination of oncolytic virotherapy and immunotherapy for glioma","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0116","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12915-019-0678-9","article-title":"Viral hijacking of cellular metabolism","volume":"17","author":"Thaker","year":"2019","journal-title":"BMC Biology"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.002_bib0117","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00262-011-1045-z","article-title":"Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors","volume":"60","author":"Thomas","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/bs.acr.2026.02.002_bib0118","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.omto.2023.08.014","article-title":"Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection","volume":"30","author":"Thomas","year":"2023","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.002_bib0119","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.002_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109801","article-title":"Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity","volume":"9","author":"Tosic","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0121","article-title":"IL-12-mediated toxicity from localized oncolytic virotherapy can be reduced using systemic TNF blockade","volume":"32","author":"Valenzuela-Cardenas","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.002_bib0122","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004770","article-title":"TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy","volume":"10","author":"Valenzuela-Cardenas","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.002_bib0123","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jcyt.2015.12.007","article-title":"Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells","volume":"18","author":"Villa","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/bs.acr.2026.02.002_bib0124","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.omto.2020.06.011","article-title":"Autologous transplantation using donor leukocytes loaded ex vivo with oncolytic myxoma virus can eliminate residual multiple myeloma","volume":"18","author":"Villa","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/bs.acr.2026.02.002_bib0125","doi-asserted-by":"crossref","first-page":"490","DOI":"10.18632\/oncotarget.28205","article-title":"Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma","volume":"13","author":"Villa","year":"2022","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/bs.acr.2026.02.002_bib0126","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood-2014-07-587329","article-title":"Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells","volume":"125","author":"Villa","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.002_bib0127","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/bs.acr.2026.02.002_bib0128","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.002_bib0129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000099","article-title":"RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages","volume":"4","author":"Wang","year":"2008","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.002_bib0130","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/ni1132","article-title":"Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier","volume":"5","author":"Wang","year":"2004","journal-title":"Nat Immunol"},{"issue":"13","key":"10.1016\/bs.acr.2026.02.002_bib0131","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1128\/JVI.78.13.7097-7111.2004","article-title":"Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak","volume":"78","author":"Wang","year":"2004","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.002_bib0132","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1073\/pnas.0509341103","article-title":"Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor","volume":"103","author":"Wang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"42","key":"10.1016\/bs.acr.2026.02.002_bib0133","doi-asserted-by":"crossref","first-page":"21113","DOI":"10.1073\/pnas.1909414116","article-title":"Cowpox virus encodes a protein that binds B7.1 and B7.2 and subverts T cell costimulation","volume":"116","author":"Wang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.acr.2026.02.002_bib0134","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1476-4598-13-82","article-title":"Targeting gallbladder cancer: Oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo","volume":"13","author":"Weng","year":"2014","journal-title":"Mol Cancer"},{"key":"10.1016\/bs.acr.2026.02.002_bib0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-3527(08)00003-1","article-title":"Poxvirus host range genes","volume":"71","author":"Werden","year":"2008","journal-title":"Adv Virus Res"},{"issue":"19","key":"10.1016\/bs.acr.2026.02.002_bib0136","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194703","article-title":"Dual-armed oncolytic myxoma virus encoding IFN-\u03b3 and CD47 promotes lymphocyte infiltration and tumor suppression of syngeneic murine melanoma","volume":"15","author":"Woo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.acr.2026.02.002_bib0137","doi-asserted-by":"crossref","DOI":"10.1177\/1179554921993069","article-title":"The oncolytic activity of myxoma virus against soft tissue sarcoma is mediated by the overexpression of ribonucleotide reductase","volume":"15","author":"Woo","year":"2021","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/bs.acr.2026.02.002_bib0138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103014","article-title":"Opportunities and challenges for non-small cell lung cancer brain metastases in the immunotherapy era","volume":"140","author":"Yu","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.002_bib0139","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/neuonc\/not035","article-title":"Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin","volume":"15","author":"Zemp","year":"2013","journal-title":"Neuro Oncol"},{"issue":"23","key":"10.1016\/bs.acr.2026.02.002_bib0140","doi-asserted-by":"crossref","first-page":"eadh8502","DOI":"10.1126\/sciadv.adh8502","article-title":"Human SAMD9 is a poxvirus-activatable anticodon nuclease inhibiting codon-specific protein synthesis","volume":"9","author":"Zhang","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/bs.acr.2026.02.002_bib0141","first-page":"1","article-title":"The discovery and development of oncolytic viruses: Are they the future of cancer immunotherapy?","author":"Zhang","year":"2020","journal-title":"Expert Opin Drug Discov"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.002_bib0142","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.002_bib0143","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.ccell.2022.08.001","article-title":"Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance","volume":"40","author":"Zheng","year":"2022","journal-title":"Cancer Cell"}],"container-title":["Advances in Cancer Research","Viruses as Therapeutic Agents for Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:49:13Z","timestamp":1785894553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X26000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443432361"],"references-count":143,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2026.02.002","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}